E1305: Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (H-26189)
E1305: A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer (H-26189):
This study compares the effects of two different standard of care chemotherapies (cisplatin/docetaxel or cisplatin/5-FU) with or without the addition of bevacizumab to learn which treatment is better. Patients must have recurrent or metastatic Squamous Cell Cancer of the Head and Neck, not have received any prior therapy for recurrent/metastatic disease, and not have previously taken bevacizumab. After the treating physician selects which chemotherapy the patient will receive (cisplatin/docetaxel or cisplatin/5-FU), patients are randomized to either chemotherapy alone, or chemotherapy + bevacizumab.
For more information: http://www.clinicaltrials.gov/ct2/show/NCT00588770